Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Takeda Pharmaceutical Co ( (JP:4502) ) has shared an update.
Takeda Pharmaceutical Co has revised its financial forecast for FY2024, expecting a 2.5% increase in revenue to JPY 4,590.0 billion due to slower generic erosion of VYVANSE in the U.S., favorable foreign exchange rates, and strong business momentum. The operating profit is projected to rise by 29.8% to JPY 344.0 billion, with net profit expected to increase by 73.5% to JPY 118.0 billion. These upward revisions reflect positive impacts from VYVANSE and R&D savings, positioning Takeda strongly in the industry and signaling a robust financial performance for stakeholders.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. The company focuses on creating life-transforming treatments in areas like gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With operations in approximately 80 countries, Takeda is committed to improving patient experiences and advancing new treatment options through a diverse pipeline.
YTD Price Performance: -2.61%
Average Trading Volume: 17,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.73B
For a thorough assessment of 4502 stock, go to TipRanks’ Stock Analysis page.
